Key result
IV cyclophosphamide reduces SPAP more than oral enalapril in SLE-associated pulmonary hypertension.
Why the study?
The comparative efficacy of intravenous cyclophosphamide versus oral enalapril in mild or moderate pulmonary hypertension associated with systemic lupus erythematosus was unclear.
Does intravenous cyclophosphamide reduce systolic pulmonary artery pressure compared to enalapril in patients with systemic lupus erythematosus and mild or moderate pulmonary hypertension?
RCT (n=34)
Does intravenous cyclophosphamide reduce systolic pulmonary artery pressure compared to enalapril in patients with systemic lupus erythematosus and mild or moderate pulmonary hypertension?
p-value: p=0.04
Intravenous cyclophosphamide significantly reduces systolic pulmonary artery pressure in patients with SLE-associated pulmonary hypertension compared to enalapril, though with an increased risk of infections and gastrointestinal side effects.
No takes yet. Share an insight, caveat, or question.
Supports cyclophosphamide over enalapril for SLE-pulmonary hypertension despite infection risk; extends immunosuppression evidence in connective tissue disease PH.
González-López et al. (2004) conducted an RCT in Pulmonary hypertension associated with systemic lupus erythematosus (n=34). Intravenous cyclophosphamide vs. Oral enalapril (10 mg/day) was evaluated on Significant decrease in systolic pulmonary artery pressure (SPAP) (p=0.04). Intravenous cyclophosphamide reduced systolic pulmonary artery pressure significantly more than oral enalapril in patients with SLE-associated pulmonary hypertension (P=0.04).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: